In addition, study on the 90 patients with detailed follow-up data showed that downregulation of SNX1 in GC was significantly associated with bigger tumor size (p = 0.0294), poor tumor stage (p = 0.0285) and poor nodal status (p = 0.0286) (Table 1), and SNX1 might act as a potential prognostic marker of GC based on the survival curve analysis (Fig. 2). This evidence concerns the gene SNX1 and neoplasm.